Momelotinib: A game-changer for managing myelofibrosis with anaemia | Multidisciplinary

On November 1, 2024, the Singapore Health Sciences Authority (HSA) approved momelotinib for treating myelofibrosis in adult patients with moderate-to-severe anaemia who are either JAK inhibitor-naïve or have been treated with ruxolitinib. The approval was based on data from three pivotal trials — SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM. [Health Sciences Authority. Momelotinib (Omjjara) product information leaflet 2024]

This article explores the burden of anaemia in myelofibrosis, the evidence supporting momelotinib, and insights from renowned expert Dr Yvonne Loh, Haematologist at Curie Oncology, Singapore, on the challenges of treating myelofibrosis and momelotinib’s evolving role.

Resources

Momelotinib: A game-changer for managing myelofibrosis with anaemia